-
1 Comment
Aurinia Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.0.
Aurinia Pharmaceuticals Inc's total revenue rose by 172417.2% to $50M since the same quarter in the previous year.
Its net income has increased by 89.4% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 106.8% to $2M since the same quarter in the previous year.
Based on the above factors, Aurinia Pharmaceuticals Inc gets an overall score of 4/5.
| ISIN | CA05156V1022 |
|---|---|
| Exchange | F |
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 989M |
|---|---|
| Beta | 1.22 |
| PE Ratio | 179.2 |
| Target Price | 28.33 |
| Dividend Yield | None |
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IKAP.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
